 This trial combines dose dense chemotherapy with Doxorubicin and Cyclophosphamide AC followed by standard every 3 week docetaxel and GW572016 for neoadjuvant treatment of her2neu positive stage IIIII breast cancer. GW572016 or Lapatinib, the investigational agent, acts as a duel inhibitor of both epidermal growth factor receptor EGFR and ErbB-2 Her2neu tyrosine kinase activity. EGFR and ErbB2 receptors are frequently over-expressed or altered in human cancers including breast cancer. This study plans to determine the antitumor activity of this regimen and its effectiveness of preventing tumor growth and spread. 